Real-time Stock quotes, portfolio, LIVE TV and more.
Aug 22, 2011, 07.39 PM IST
Biotech firm Biocon today said its unit 'Clinigene International' has inked a pact with US-based Spaulding Clinical Research to jointly offer clinical research solutions to both pharma as well as biotech firms.
This partnership establishes a cost-efficient global footprint for clinical pharmacology services, providing an opportunity for both organisations to engage pharmaceutical clients strategically, Biocon said in a statement.
Clinigene Chief Operating Officer Abhijit Barve said: "Pharmaceutical clients globally are increasingly seeking strategies to expedite their early clinical development, streamlining processes while maintaining high quality.
"Our strategic partnership is designed to deliver this in a very cost-effective manner."
The company, however, did not disclose financial details.
"With Clinigene's expertise and cost-effective approach... Our clients are able to easily structure a program for their compound that delivers high-value value," Spaulding Clinical CEO Randol Spaulding said.
Shares of Biocon today closed at Rs 329.20 on the Bombay Stock Exchange, up 2.01% from its previous close.
Tags: Biocon, Clinigene International, pharma, Spaulding Clinical Research, Abhijit Barve, Randol Spaulding
May 20 2013, 15:05
- in MARKET OUTLOOK
May 20 2013, 12:21
- in Commodities